Edesa Gets $12 Million Upfront in Japan Experimental Drug License With Kyorin

Key Facts

Edesa Biotech and Kyorin Pharmaceutical entered into a license and collaboration agreement on November 8, 2026, and Edesa announced the deal the following day, granting Kyorin exclusive rights to develop and market paridiprubart to treat acute respiratory distress syndrome in Japan. Edesa will receive a nonrefundable upfront payment of $12 million under the agreement. The company may receive up to $55 million upon reaching development and regulatory milestones, and up to ¥12.0 billion in sales-related milestones. The deal also includes tiered low-double-digit royalties on net sales in Japan. No documented percentage gain in the stock during the deal-announcement session is available; the last close before the announcement was $2.14 on November 6.

The payment structure places the $12 million upfront payment on signing, while the larger payments remain contingent on later milestones. The $55 million ceiling covers development and regulatory milestones, while the ¥12.0 billion ceiling is tied to sales. Edesa would also benefit from royalties on net sales in Japan if the drug reaches the market and generates sales there. But the disclosure states that reaching future milestones and receiving the associated payments are not guaranteed. Regulatory approvals and suitable national pricing in Japan are also factors that could affect commercial success.

Under the agreement, Kyorin will generally fund development, regulatory activities and marketing in Japan. Edesa retains rights to paridiprubart outside the licensed territory, including the United States, Europe and Canada, as well as manufacturing and supply rights. The agreement gives Kyorin a first right to negotiate use of the drug to treat acute kidney injury. It also gives Kyorin a nonexclusive right to negotiate certain other indications in Japan. The agreement thus broadens the potential scope of cooperation in the Japanese market while Edesa retains rights in other territories.

Paridiprubart is an experimental monoclonal antibody that targets the TLR4 receptor, according to Kyorin. The company describes acute respiratory distress syndrome as a serious condition associated with substantial mortality and says there are limited proven drug treatment options that improve survival. Kyorin’s president said the condition is extremely severe and requires intensive care, and that the company is seeking with Edesa to accelerate global clinical development, including in Japan. These statements describe a stated development goal, while the drug remains experimental. The license itself does not mean the drug has received regulatory approval or been launched commercially.

In earlier clinical data reported by Edesa, an exploratory analysis included 174 patients who did not meet the study’s criteria based on invasive mechanical ventilation. The company said adjusted 28-day mortality risks were 15% in the paridiprubart group versus 23% in the placebo group, with a p-value below 0.005. Edesa described the analysis as exploratory, which defines the nature of the reported result. It also said Phase 3 results were selected for oral presentations at meetings of the American Thoracic Society and the European Renal Association. The data provide some of the clinical background accompanying the licensing agreement as evaluation of the drug continues.

The clinical program continues alongside the Japan agreement; in February 2026, Edesa disclosed a U.S. government-funded study in patients with acute respiratory distress syndrome and said enrollment was ongoing for the company’s cohort, which targets about 200 participants. The official record for the JUST BREATHE study describes it as a Phase 2 platform study testing multiple treatment options for adults hospitalized with the condition, including paridiprubart. The record estimates total enrollment at about 600 participants and lists completion of the primary phase in July 2028 and study completion in September 2028. These are estimated dates listed in the record, not an announcement that the study has been completed. Kyorin’s president said the companies are seeking to accelerate global clinical development, while payments tied to future milestones remain subject to achieving those milestones and obtaining the necessary approvals.